AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

As the doctors told Annette Stalley she might need to be put on a ventilator, she realised it was a situation of her own ...

For those reliant on inhalers or other medications, Breathe presents a complementary ... For those struggling with asthma, COPD, or other respiratory issues, Breathe represents a promising option ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...